GSK's $4 Billion Asthma Drug Gets First-Ever Green Light in Europe
I'm PortAI, I can summarize articles.
GSK's asthma drug, depemokimab, received its first global regulatory endorsement from Europe's drug regulator, recommended as an add-on therapy for severe asthma and chronic rhinosinusitis with nasal polyps. The drug showed a 54% reduction in serious asthma attacks and requires dosing only twice a year. GSK plans to launch it between 2026 and 2027, potentially generating $4 billion in annual sales, pending final approval from the European Commission expected in early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments